vs
Esperion Therapeutics, Inc.（ESPR）与GERMAN AMERICAN BANCORP, INC.（GABC）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是GERMAN AMERICAN BANCORP, INC.的1.3倍（$168.4M vs $126.7M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 39.7%），过去两年GERMAN AMERICAN BANCORP, INC.的营收复合增速更高（22.7% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
German American Bancorp, Inc.（股票代码：GABC）是一家美国的银行控股企业，专注于提供多元金融服务，核心业务涵盖支付卡相关服务，总部位于纽约曼哈顿下城的巴特利公园城，在金融服务领域拥有成熟的业务布局。
ESPR vs GABC — 直观对比
营收规模更大
ESPR
是对方的1.3倍
$126.7M
营收增速更快
ESPR
高出104.0%
39.7%
两年增速更快
GABC
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $126.7M |
| 净利润 | — | $35.7M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 34.6% |
| 净利率 | — | 28.2% |
| 营收同比 | 143.7% | 39.7% |
| 净利润同比 | — | 53.7% |
| 每股收益（稀释后） | $0.32 | $0.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRGABC
| Q4 25 | $168.4M | $126.7M | ||
| Q3 25 | $87.3M | $126.5M | ||
| Q2 25 | $82.4M | $123.2M | ||
| Q1 25 | $65.0M | $111.1M | ||
| Q4 24 | $69.1M | $90.7M | ||
| Q3 24 | $51.6M | $88.5M | ||
| Q2 24 | $73.8M | $90.5M | ||
| Q1 24 | $137.7M | $84.1M |
净利润ESPRGABC
| Q4 25 | — | $35.7M | ||
| Q3 25 | $-31.3M | $35.1M | ||
| Q2 25 | $-12.7M | $31.4M | ||
| Q1 25 | $-40.5M | $10.5M | ||
| Q4 24 | — | $23.2M | ||
| Q3 24 | $-29.5M | $21.0M | ||
| Q2 24 | $-61.9M | $20.5M | ||
| Q1 24 | $61.0M | $19.0M |
营业利润率ESPRGABC
| Q4 25 | 50.6% | 34.6% | ||
| Q3 25 | -11.4% | 34.6% | ||
| Q2 25 | 8.6% | 31.8% | ||
| Q1 25 | -34.0% | 12.0% | ||
| Q4 24 | -6.4% | 31.6% | ||
| Q3 24 | -31.0% | 29.0% | ||
| Q2 24 | 3.5% | 29.4% | ||
| Q1 24 | 52.5% | 27.6% |
净利率ESPRGABC
| Q4 25 | — | 28.2% | ||
| Q3 25 | -35.9% | 27.7% | ||
| Q2 25 | -15.4% | 25.5% | ||
| Q1 25 | -62.2% | 9.5% | ||
| Q4 24 | — | 25.6% | ||
| Q3 24 | -57.2% | 23.8% | ||
| Q2 24 | -83.9% | 22.7% | ||
| Q1 24 | 44.3% | 22.6% |
每股收益（稀释后）ESPRGABC
| Q4 25 | $0.32 | $0.98 | ||
| Q3 25 | $-0.16 | $0.94 | ||
| Q2 25 | $-0.06 | $0.84 | ||
| Q1 25 | $-0.21 | $0.30 | ||
| Q4 24 | $-0.14 | $0.79 | ||
| Q3 24 | $-0.15 | $0.71 | ||
| Q2 24 | $-0.33 | $0.69 | ||
| Q1 24 | $0.34 | $0.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | — |
| 总债务越低越好 | — | $100.0M |
| 股东权益账面价值 | $-302.0M | $1.2B |
| 总资产 | $465.9M | $8.4B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资ESPRGABC
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
总债务ESPRGABC
| Q4 25 | — | $100.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $114.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ESPRGABC
| Q4 25 | $-302.0M | $1.2B | ||
| Q3 25 | $-451.4M | $1.1B | ||
| Q2 25 | $-433.5M | $1.1B | ||
| Q1 25 | $-426.2M | $1.0B | ||
| Q4 24 | $-388.7M | $715.1M | ||
| Q3 24 | $-370.2M | $744.6M | ||
| Q2 24 | $-344.2M | $687.8M | ||
| Q1 24 | $-294.3M | $655.3M |
总资产ESPRGABC
| Q4 25 | $465.9M | $8.4B | ||
| Q3 25 | $364.0M | $8.4B | ||
| Q2 25 | $347.1M | $8.3B | ||
| Q1 25 | $324.0M | $8.4B | ||
| Q4 24 | $343.8M | $6.3B | ||
| Q3 24 | $314.1M | $6.3B | ||
| Q2 24 | $352.3M | $6.2B | ||
| Q1 24 | $373.1M | $6.1B |
负债/权益比ESPRGABC
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $159.3M |
| 自由现金流经营现金流 - 资本支出 | — | $154.0M |
| 自由现金流率自由现金流/营收 | — | 121.6% |
| 资本支出强度资本支出/营收 | 0.0% | 4.2% |
| 现金转化率经营现金流/净利润 | — | 4.46× |
| 过去12个月自由现金流最近4个季度 | — | $267.0M |
8季度趋势，按日历期对齐
经营现金流ESPRGABC
| Q4 25 | $45.2M | $159.3M | ||
| Q3 25 | $-4.3M | $51.8M | ||
| Q2 25 | $-31.4M | $26.9M | ||
| Q1 25 | $-22.6M | $37.9M | ||
| Q4 24 | $-35.0M | $95.8M | ||
| Q3 24 | $-35.3M | $24.5M | ||
| Q2 24 | $-7.2M | $18.7M | ||
| Q1 24 | $53.8M | $23.9M |
自由现金流ESPRGABC
| Q4 25 | — | $154.0M | ||
| Q3 25 | — | $50.1M | ||
| Q2 25 | — | $26.2M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | — | $90.7M | ||
| Q3 24 | $-35.5M | $23.0M | ||
| Q2 24 | $-7.3M | $17.0M | ||
| Q1 24 | $53.8M | $22.6M |
自由现金流率ESPRGABC
| Q4 25 | — | 121.6% | ||
| Q3 25 | — | 39.6% | ||
| Q2 25 | — | 21.2% | ||
| Q1 25 | — | 33.0% | ||
| Q4 24 | — | 100.1% | ||
| Q3 24 | -68.7% | 26.0% | ||
| Q2 24 | -9.9% | 18.8% | ||
| Q1 24 | 39.0% | 26.9% |
资本支出强度ESPRGABC
| Q4 25 | 0.0% | 4.2% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.0% | 1.1% | ||
| Q4 24 | 0.0% | 5.6% | ||
| Q3 24 | 0.3% | 1.7% | ||
| Q2 24 | 0.1% | 1.8% | ||
| Q1 24 | 0.1% | 1.5% |
现金转化率ESPRGABC
| Q4 25 | — | 4.46× | ||
| Q3 25 | — | 1.48× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | 3.61× | ||
| Q4 24 | — | 4.13× | ||
| Q3 24 | — | 1.16× | ||
| Q2 24 | — | 0.91× | ||
| Q1 24 | 0.88× | 1.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
GABC
暂无分部数据
